Artivion | CRY - Selling And Administration Expenses


Artivion reported $55.75M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Abbott USD 4.27B 669M Sep/2026
Accuray USD 124.78M 2.54M Dec/2025
AngioDynamics USD 36.57M 3.79M Sep/2025
Artivion USD 55.75M 4.54M Dec/2025
AtriCure USD 82.88M 319K Sep/2026
Baxter International USD 730M 5M Sep/2026
Becton, Dickinson and Co. USD 1.26B 1000K Sep/2026
Boston Scientific USD 1.68B 120M Sep/2026
Edwards Lifesciences USD 560.9M 300K Sep/2026
Inogen USD 43.77M 510K Jun/2024
Integra LifeSciences USD 161.02M 5.2M Sep/2026
J&J USD 6.25B 168M Sep/2026
Mesa Laboratories USD 27.31M 380K Sep/2024
Orthofix International USD 130.35M 11.31M Dec/2025
Pfizer USD 3.28B 132M Sep/2026
ResMed USD 290.65M 10.86M Jun/2026
Stryker USD 2.12B 32M Jun/2026
Tandem Diabetes Care USD 113.94M 2.3M Sep/2026
Teleflex USD 220.72M 7.21M Sep/2026
Terumo JPY 109.58B 120M Sep/2026
Trinity Biotech USD 4.71M 1.08M Mar/2026